In vitro model: Evercyte´s in vitro bioassays to test compounds for a potential to alter cytokine release are based on human telomerized cells from different tissues and organs (e.g. skin, cornea, lung, vascular system, kidney, placenta). Assay set-up:
treatment of telomerized cells with compounds followed by measurement of cytokine release using different methods such as western blotting, ELISA or Luminex.Timelines:
depending on the number of compounds to be tested, the number of replicates and concentrations requested, it takes between 3 and 6 weeks to deliver results.
Testing the response of fibroblasts to Interleukin-17A treatment
release of Interleukin-6 upon Interleukin-17A treatment
Treatment of human dermal fibroblasts (fHDF/TERT166) with Interleukin-17A (IL17A) results in expression of Interleukin-6 (IL6) in a concentration dependent manner. This model system therefore allows screening for compounds that inhibit the cellular response to IL17A and subsequently counteract the pro-inflammatory activity of IL17A and tissue inflammation.